Physician profile
Peter S Kim
NPI 1235157017
$13,090.31
in general payments reported to CMS, 2019-2025
31 companies · $769 in 2025
The $769 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,641 · 2020: $587 · 2021: $88.05 · 2022: $399 · 2023: $298 · 2024: $8,309 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,360 · Food and Beverage: $1,936 · Travel and Lodging: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,360.00 |
| Food and Beverage | $1,936.37 |
| Travel and Lodging | $1,079.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $7,685.79 | 2024 | |
| Abbvie INC. | $1,379.23 | 2019-2025 | |
| Janssen Biotech, INC. | $484.11 | 2019-2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $462.04 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $426.10 | 2019-2025 | Entyvio |
| Qol Medical, LLC | $303.04 | 2019-2024 | Sucraid |
| Lilly USA, LLC | $276.28 | 2024-2025 | Omvoh |
| Allergan, INC. | $248.27 | 2019 | |
| Gilead Sciences, INC. | $204.06 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $160.70 | 2019-2023 | Dificid |
| Braintree Laboratories, INC. | $152.38 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $151.47 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $141.76 | 2024 | Voquezna |
| Celgene Corporation | $134.42 | 2022-2024 | Zeposia |
| Pfizer INC. | $119.42 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $103.02 | 2022 | |
| Ethicon US, LLC | $103.02 | 2022 | |
| Ferring Pharmaceuticals INC. | $102.95 | 2019 | |
| Cook Medical LLC | $80.82 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $54.36 | 2025 | Dupixent |
| Boston Scientific Corporation | $51.70 | 2022-2023 | |
| Romark Laboratories, Lc | $46.94 | 2019-2020 | |
| Ucb, INC. | $37.30 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $31.33 | 2019 | |
| Ardelyx, INC. | $29.50 | 2023 | Ibsrela |
| Exact Sciences Corporation | $29.33 | 2025 | Cologuard Collection Kit |
| Alfasigma USA, INC. | $22.94 | 2020 | |
| Endo Pharmaceuticals INC. | $20.20 | 2020 | |
| Napo Pharmaceuticals INC | $19.94 | 2019 | |
| Shire North American Group INC | $15.19 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.